IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M | N/A | N/A | N/A |
| Cost of Revenue | $3.83M | $4.01M | $2.10M | $1.73M | $1.38M | $1.25M | $886.00K | $391.00K |
| Gross Profit | $3.17M | $19.38M | $48.83M | $26.22M | $18.16M | $-1.25M | $-886.00K | $-391.00K |
| Gross Margin | 45.23% | 82.86% | 95.87% | 93.83% | 92.93% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $330.14M | $153.81M | $111.33M | $76.48M | $53.50M | $43.03M | $35.53M | $14.05M |
| Operating Income | $-326.98M | $-134.43M | $-62.50M | $-50.27M | $-35.34M | $-44.27M | $-36.42M | $-14.44M |
| Operating Margin | -4671.07% | -574.85% | -122.72% | -179.91% | -180.90% | 0.00% | 0.00% | 0.00% |
| Net Income | $-274.48M | $-112.96M | $-58.66M | $-49.76M | $-34.49M | $-41.98M | $-34.35M | $-11.86M |
| Net Margin | -3921.10% | -483.05% | -115.17% | -178.10% | -176.55% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.31 | $-1.90 | $-2.41 | $-0.83 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |